Table 2.

Effect of GPCR receptor antagonists on diabetic Parkinson’s disease autoantibody-induced neurite retraction.

Antagonist	[Conc]	GPRC	%Neutralization of Diabetic PD Autoantibody Neurite Retraction
M100907	200 nM	5-HT2A	95%
Spiperone	200 nM	5-HT2A	90%
Ketanserin	200 nM	5-HT2A	60%
SB 204741	1 μM	5-HT2B	10%
Losartan	10 μM	AT-1R	20%
Bosentan	10 μM	ET1-R	15%
Prazosin	2 μM	A1-AR	0%

Results are expressed as mean of two determinations (which varied by < 15%) and were calculated as 1-[neurite length in presence of antagonist + diab PD autoantibodies (~60 nM) divided by (neurite length in presence of diab PD autoantibodies alone)] x 100.